Lixte Biotechnology Holdings Stock Alpha and Beta Analysis

LIXT Stock  USD 1.63  0.11  7.24%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Lixte Biotechnology Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Lixte Biotechnology over a specified time horizon. Remember, high Lixte Biotechnology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Lixte Biotechnology's market risk premium analysis include:
Beta
(0.86)
Alpha
0.12
Risk
9.02
Sharpe Ratio
0.0016
Expected Return
0.0148
Please note that although Lixte Biotechnology alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Lixte Biotechnology did 0.12  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Lixte Biotechnology Holdings stock's relative risk over its benchmark. Lixte Biotechnology has a beta of 0.86  . As the market becomes more bullish, returns on owning Lixte Biotechnology are expected to decrease slowly. On the other hand, during market turmoil, Lixte Biotechnology is expected to outperform it slightly. At this time, Lixte Biotechnology's Book Value Per Share is comparatively stable compared to the past year. Tangible Book Value Per Share is likely to gain to 2.27 in 2024, despite the fact that Enterprise Value is likely to grow to (5 M).

Enterprise Value

(4.97 Million)

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Lixte Biotechnology Backtesting, Lixte Biotechnology Valuation, Lixte Biotechnology Correlation, Lixte Biotechnology Hype Analysis, Lixte Biotechnology Volatility, Lixte Biotechnology History and analyze Lixte Biotechnology Performance.

Lixte Biotechnology Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Lixte Biotechnology market risk premium is the additional return an investor will receive from holding Lixte Biotechnology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Lixte Biotechnology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Lixte Biotechnology's performance over market.
α0.12   β-0.86

Lixte Biotechnology expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Lixte Biotechnology's Buy-and-hold return. Our buy-and-hold chart shows how Lixte Biotechnology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Lixte Biotechnology Market Price Analysis

Market price analysis indicators help investors to evaluate how Lixte Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Lixte Biotechnology shares will generate the highest return on investment. By understating and applying Lixte Biotechnology stock market price indicators, traders can identify Lixte Biotechnology position entry and exit signals to maximize returns.

Lixte Biotechnology Return and Market Media

The median price of Lixte Biotechnology for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 1.84 with a coefficient of variation of 9.01. The daily time series for the period is distributed with a sample standard deviation of 0.16, arithmetic mean of 1.83, and mean deviation of 0.12. The Stock received some media coverage during the period.
 Price Growth (%)  
       Timeline  
1
LIXT - Lixte Biotechnology Holdings, Inc. Latest Stock News Market Updates - StockTitan
09/04/2024
2
Acquisition by Forman Eric of 1112 shares of Lixte Biotechnology at 0.63 subject to Rule 16b-3
10/04/2024
3
Acquisition by Forman Eric of 6059 shares of Lixte Biotechnology at 0.5593 subject to Rule 16b-3
11/15/2024
4
Acquisition by Van Der Baan Bastiaan Jeroen of 10000 shares of Lixte Biotechnology at 5.88 subject to Rule 16b-3
11/18/2024

About Lixte Biotechnology Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Lixte or other stocks. Alpha measures the amount that position in Lixte Biotechnology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2010 2023 2024 (projected)
Dividend Yield8.56E-40.0016130.001059
Price To Sales Ratio11.6910.529.35

Lixte Biotechnology Upcoming Company Events

As portrayed in its financial statements, the presentation of Lixte Biotechnology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lixte Biotechnology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Lixte Biotechnology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Lixte Biotechnology. Please utilize our Beneish M Score to check the likelihood of Lixte Biotechnology's management manipulating its earnings.
3rd of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

Build Portfolio with Lixte Biotechnology

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.